What changed, and where the recommendation applies
Lenacapavir is a long-acting capsid inhibitor used as an additional PrEP option. WHO recommended twice-yearly injectable lenacapavir in July 2025. This is a prevention option, not a vaccine or a cure for HIV, and it does not remove the need for clinical care. [1]
CDC reported US FDA approval in June 2025 and issued a US recommendation that September. Those decisions do not establish current Thai authorization, stock, eligibility, price or insurance coverage. Confirm local availability with an appropriate service rather than relying on a prediction in an older article. [2]
Strong evidence is not a guarantee for every person
PURPOSE 1 and PURPOSE 2 support high efficacy, but “zero infections in both trials” is inaccurate: CDC reports infections in PURPOSE 2. Trial percentages describe specified populations, comparisons and follow-up, not a personal guarantee. CDC did not evaluate a direct randomized comparison with injectable cabotegravir. [2]
WHO frames lenacapavir as another choice alongside existing PrEP methods, not proof that one option is best for everyone. Access, preferences, medical assessment and support all matter. An injection does not itself eliminate stigma or practical barriers. [1]
Long acting still requires assessment and follow-up
A qualified team must exclude HIV, check interacting medicines and plan follow-up. Starting treatment involves more than a single generic injection. Do not obtain, prepare, inject, stop or switch medicines using this article. Injection-site reactions, including nodules that may persist, need an explanation and a plan for concerns. [2]
If a visit is delayed, you want to stop, or an exposure occurs, contact the prescribing service promptly for an individual plan. Do not assume protection continues indefinitely or replace it with borrowed PrEP. Different products and routes have different evidence and requirements. [3]
Testing, other prevention and urgent care remain important
HIV testing must fit the product and clinical situation. A home oral antibody test alone is not a universal clearance to start an injectable product; prevention medicines can affect interpretation. A reactive screen requires confirmation and an invalid test is not negative. [4] [3] [2]
PrEP does not prevent all other sexually transmitted infections or pregnancy. Discuss condoms, STI care and sterile injection equipment according to actual exposure, without judging identity, occupation or number of partners. [3] [5] [6]
Seek PEP assessment as soon as possible after a possible HIV exposure and start when indicated within 72 hours. Do not wait for symptoms, all pending laboratory results or an online appointment. If more time has passed, still seek assessment and a testing plan. Do not substitute PrEP yourself. [7]
Frequently asked questions
What changed, and where the recommendation applies
Lenacapavir is a long-acting capsid inhibitor used as an additional PrEP option. WHO recommended twice-yearly injectable lenacapavir in July 2025. This is a prevention option, not a vaccine or a cure for HIV, and it does not remove the need for clinical care. [1]
Strong evidence is not a guarantee for every person
PURPOSE 1 and PURPOSE 2 support high efficacy, but “zero infections in both trials” is inaccurate: CDC reports infections in PURPOSE 2. Trial percentages describe specified populations, comparisons and follow-up, not a personal guarantee. CDC did not evaluate a direct randomized comparison with injectable cabotegravir. [2]
Long acting still requires assessment and follow-up
A qualified team must exclude HIV, check interacting medicines and plan follow-up. Starting treatment involves more than a single generic injection. Do not obtain, prepare, inject, stop or switch medicines using this article. Injection-site reactions, including nodules that may persist, need an explanation and a plan for concerns. [2]
Testing, other prevention and urgent care remain important
HIV testing must fit the product and clinical situation. A home oral antibody test alone is not a universal clearance to start an injectable product; prevention medicines can affect interpretation. A reactive screen requires confirmation and an invalid test is not negative. [4] [3] [2]
Summary
Lenacapavir is a long-acting capsid inhibitor used as an additional PrEP option. WHO recommended twice-yearly injectable lenacapavir in July 2025. This is a prevention option, not a vaccine or a cure for HIV, and it does not remove the need for clinical care. [1]
ลิงก์และภาพประกอบเดิม
เก็บลิงก์เดิมไว้สำหรับการเข้าถึงข้อมูลประกอบ ไม่ใช้รับรองคำแนะนำทางการแพทย์ ราคา หรือเงื่อนไขปัจจุบัน
Illustrative stock image, not a verified photograph of lenacapavir or instructions for preparing or injecting it. A qualified service must provide the prescribed product. [2]
หมายเหตุ บทความนี้ให้ข้อมูลความรู้ทั่วไป ไม่ใช่การวินิจฉัย และไม่ใช่คำแนะนำการใช้ยาเฉพาะบุคคล เรื่องยาและการรักษาเป็นการตัดสินใจร่วมกับแพทย์หรือเภสัชกรที่ดูแลคุณ ไม่ควรซื้อ เริ่ม หยุด หรือปรับยาด้วยตัวเอง หากมีข้อสงสัยเกี่ยวกับสุขภาพของตัวเอง ปรึกษาเจ้าหน้าที่สาธารณสุขหรือคลินิกใกล้บ้านได้เสมอ
อ้างอิงตามข้อความที่ตรวจทาน
- WHO: Recommends injectable lenacapavir as an additional PrEP option, July 2025
- CDC MMWR: Lenacapavir PrEP recommendation, United States, September 2025
- CDC (สหรัฐฯ): การประเมินและติดตาม PrEP
- CDC (สหรัฐฯ): การตรวจ HIV และช่วงหน้าต่าง
- CDC (สหรัฐฯ): การใช้ถุงยางและการจัดการเมื่อถุงยางแตก
- CDC (สหรัฐฯ): ช่องทางถ่ายทอด HIV
- CDC (สหรัฐฯ): แนวทาง PEP ปี 2025
ตรวจทานและปรับปรุงเนื้อหา: 29 ตุลาคม 2569

